SB-228357

From WikiMD's WELLNESSPEDIA

SB-228357 is a serotonin receptor agonist that was discovered and developed by SmithKline Beecham. It is a potent and selective 5-HT4 receptor agonist, with a pKi of 9.5, and has been used in scientific research to study the function of the 5-HT4 receptor.

History[edit]

SB-228357 was first discovered and developed by the pharmaceutical company SmithKline Beecham. The compound was identified as a potent and selective 5-HT4 receptor agonist, which made it a valuable tool in scientific research to study the function of the 5-HT4 receptor.

Pharmacology[edit]

SB-228357 is a potent and selective 5-HT4 receptor agonist. The 5-HT4 receptor is one of the several different subtypes of the serotonin receptor, which is a group of G protein-coupled receptors that are targeted by a variety of drugs used in the treatment of various disorders, including depression, anxiety, and migraine.

Research[edit]

SB-228357 has been used in scientific research to study the function of the 5-HT4 receptor. The compound's potent and selective agonist activity at the 5-HT4 receptor makes it a valuable tool in this research.

See also[edit]

Stub icon

This medical article is a stub. You can help WikiMD by expanding the page.


References[edit]


External links[edit]

SB-228357[edit]

  • SB-228357 structure
    SB-228357 structure

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=SB-228357&oldid=6333078"